JP2024543111A - 胃がんの治療に使用するための化合物 - Google Patents

胃がんの治療に使用するための化合物 Download PDF

Info

Publication number
JP2024543111A
JP2024543111A JP2024529934A JP2024529934A JP2024543111A JP 2024543111 A JP2024543111 A JP 2024543111A JP 2024529934 A JP2024529934 A JP 2024529934A JP 2024529934 A JP2024529934 A JP 2024529934A JP 2024543111 A JP2024543111 A JP 2024543111A
Authority
JP
Japan
Prior art keywords
formula
pharma
halo
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543111A5 (enExample
Inventor
ビシュヌダス，ビベク・ケイ
Original Assignee
ビーピージーバイオ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビーピージーバイオ，インコーポレイテッド filed Critical ビーピージーバイオ，インコーポレイテッド
Publication of JP2024543111A publication Critical patent/JP2024543111A/ja
Publication of JP2024543111A5 publication Critical patent/JP2024543111A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024529934A 2021-11-17 2022-11-17 胃がんの治療に使用するための化合物 Pending JP2024543111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280540P 2021-11-17 2021-11-17
US63/280,540 2021-11-17
PCT/US2022/050289 WO2023091590A1 (en) 2021-11-17 2022-11-17 Compounds for use in treating gastric cancer

Publications (2)

Publication Number Publication Date
JP2024543111A true JP2024543111A (ja) 2024-11-19
JP2024543111A5 JP2024543111A5 (enExample) 2025-11-18

Family

ID=84887956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529934A Pending JP2024543111A (ja) 2021-11-17 2022-11-17 胃がんの治療に使用するための化合物

Country Status (8)

Country Link
US (1) US20250017906A1 (enExample)
EP (1) EP4433051A1 (enExample)
JP (1) JP2024543111A (enExample)
KR (1) KR20240149878A (enExample)
CN (1) CN118488837A (enExample)
AU (1) AU2022390803A1 (enExample)
CA (1) CA3238430A1 (enExample)
WO (1) WO2023091590A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020417293A1 (en) * 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
WO2024216283A1 (en) * 2023-04-13 2024-10-17 Bpgbio, Inc. Microtubule targeting agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020055906A1 (en) * 2018-09-10 2020-03-19 Berg Llc Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
US11091447B2 (en) * 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308617B2 (en) * 2016-06-03 2019-06-04 An2H Discovery Limited Triazole benzamide derivatives and the compositions and methods of treatment regarding the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020055906A1 (en) * 2018-09-10 2020-03-19 Berg Llc Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
US11091447B2 (en) * 2020-01-03 2021-08-17 Berg Llc UBE2K modulators and methods for their use

Also Published As

Publication number Publication date
EP4433051A1 (en) 2024-09-25
US20250017906A1 (en) 2025-01-16
WO2023091590A1 (en) 2023-05-25
CA3238430A1 (en) 2023-05-25
CN118488837A (zh) 2024-08-13
KR20240149878A (ko) 2024-10-15
AU2022390803A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
AU2020305979B2 (en) Method for treating idiopathic pulmonary fibrosis
JP5907396B2 (ja) 腫瘍融解症候群の治療薬及び予防薬
JP2024539228A (ja) 含窒素四環式化合物、その調製方法及びその医薬的使用
CN103214484A (zh) 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
TW201919612A (zh) 包含帕博西尼（ｐａｌｂｏｃｉｃｌｉｂ）及６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧基苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－甲酸的組合
AU2022390803A1 (en) Compounds for use in treating gastric cancer
JP2024095711A (ja) 可溶性グアニル酸シクラーゼ活性化薬としてのアルコキシピラゾール
CA2550064A1 (en) Methods of treating acute inflammation in animals with p38 map kinase inhibitors
JP2025533719A (ja) がんの治療のためのｋａｔ６阻害剤を含む投与レジメン
CA2464309C (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
JP2020518649A5 (enExample)
CA3022195C (en) Compounds for modulating aquaporins
CA3205023A1 (en) Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
US20250170079A1 (en) Combinations of stat-inhibitors and immune checkpoint inhibitors for the treatment and/or management of cancer
KR20220035143A (ko) 사이클릭 디옥시리보뉴클레오티드 화합물
JP2024523558A5 (enExample)
JPS5823688A (ja) グアニジン誘導体、その製法及びこの化合物を含むヒスタミンｈ−２−「きつ」抗性で胃酸の分泌を抑制する医薬組成物
AU2024229823B2 (en) Compositions and methods for making and using small molecules for the treatment of health conditions
WO2025202900A1 (en) Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
CN113966329B (zh) 作为pdl1检查点抑制剂的杂环免疫调节剂
JP2004115508A (ja) 熱傷皮膚組織の機能改善のための医薬
JP2022532194A (ja) Ｐｉ３ｋ阻害剤の結晶多形及びその製造方法
JP2025529076A (ja) ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
JP2022526044A (ja) ピラゾロピリミジン化合物、医薬組成物、及びその使用
JPS58203968A (ja) イソカルボスチリル誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260408